# Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging

> **NCT04776187** · PHASE4 · UNKNOWN · sponsor: **The Central Hospital of Lishui City** · enrollment: 600 (estimated)

## Conditions studied

- Nephrogenic Fibrosing Dermopathy

## Interventions

- **DRUG:** Gadodiamide
- **DRUG:** Gadoteric Acid Meglumine Salt

## Key facts

- **NCT ID:** NCT04776187
- **Lead sponsor:** The Central Hospital of Lishui City
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2021-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776187, "Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04776187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*